Details of the Drug Combination

General Information of Drug Combination (ID: DC4MBMX)

Drug Combination Name
Fluticasone Salmeterol
Indication
Disease Entry Status REF
Chronic Obstructive Pulmonary Disease Phase 4 [1]
Component Drugs Fluticasone   DMGCSVF Salmeterol   DMIEU69
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Fluticasone
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [2]
Fluticasone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Fluticasone Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [6]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Salmeterol
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [3]
Chronic obstructive pulmonary disease CA22 Approved [4]
Intrinsic asthma N.A. Approved [3]
Pulmonary emphysema CA21.Z Approved [3]
Salmeterol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [8]
------------------------------------------------------------------------------------
Salmeterol Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Salmeterol Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Decreases Expression [11]
Non-secretory ribonuclease (RNASE2) OT8Z4FNE RNAS2_HUMAN Decreases Expression [12]
Eosinophil cationic protein (RNASE3) OTVE2XD1 ECP_HUMAN Decreases Expression [13]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Increases Uptake [14]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Chronic Obstructive Pulmonary Disease DCVVFQ2 N. A. Phase 4 [1]
COPD DCVFYDT N. A. Phase 1 [15]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02055352) Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Salmeterol FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 559).
5 Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
6 Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
7 Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40.
8 Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
9 Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30.
10 Drug Interactions Flockhart Table
11 Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
12 Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur Respir J. 2002 Jul;20(1):66-72. doi: 10.1183/09031936.02.00094202.
13 Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: preliminary study in mild and moderate asthma in Trinidad, West Indies. Int J Clin Pharmacol Res. 2003;23(2-3):69-74.
14 The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J Allergy Clin Immunol. 2007 Nov;120(5):1103-9. doi: 10.1016/j.jaci.2007.08.034. Epub 2007 Oct 17.
15 ClinicalTrials.gov (NCT00568347) Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange